retatrutide clinical trials retatrutide mechanism Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide—A Game Changer in Obesity

SURMOUNT-MAINTAIN randomized patients who had lost weight on the maximum dose of tirzepatide to either continue at full dose of 10 or 15 mg, reduce to 5 mg, or switch to placebo for an additional year

In the retatrutide trial data above, dysesthesia jumped from 8.8% at the 9 mg dose to 20.9% at the 12 mg dosea pattern that mirrors whats been seen with another GLP-1 medication at a higher dose

Do not skip this step

Its biological activity is being studied through several overlapping mechanisms that may influence metabolic signaling, energy regulation, appetite pathways, and glucose or lipid metabolism

That number should alarm any bodybuilder

doi: 10.1002/jnr.22565 167 McGovernSFHunterKHolscherC